48 related articles for article (PubMed ID: 38731939)
1. Gene Expression and DNA Methylation Profiling Suggest Potential Biomarkers for Azacitidine Resistance in Myelodysplastic Syndrome.
Kim DY; Shin DY; Oh S; Kim I; Kim EJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731939
[TBL] [Abstract][Full Text] [Related]
2. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
Gill H
Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
[TBL] [Abstract][Full Text] [Related]
3. The role of next-generation sequencing in hematologic malignancies.
Cho YU
Blood Res; 2024 Mar; 59(1):11. PubMed ID: 38485897
[TBL] [Abstract][Full Text] [Related]
4. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih LY; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
NEJM Evid; 2022 Jul; 1(7):EVIDoa2200008. PubMed ID: 38319256
[TBL] [Abstract][Full Text] [Related]
5. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Khoury JD; Solary E; Abla O; Akkari Y; Alaggio R; Apperley JF; Bejar R; Berti E; Busque L; Chan JKC; Chen W; Chen X; Chng WJ; Choi JK; Colmenero I; Coupland SE; Cross NCP; De Jong D; Elghetany MT; Takahashi E; Emile JF; Ferry J; Fogelstrand L; Fontenay M; Germing U; Gujral S; Haferlach T; Harrison C; Hodge JC; Hu S; Jansen JH; Kanagal-Shamanna R; Kantarjian HM; Kratz CP; Li XQ; Lim MS; Loeb K; Loghavi S; Marcogliese A; Meshinchi S; Michaels P; Naresh KN; Natkunam Y; Nejati R; Ott G; Padron E; Patel KP; Patkar N; Picarsic J; Platzbecker U; Roberts I; Schuh A; Sewell W; Siebert R; Tembhare P; Tyner J; Verstovsek S; Wang W; Wood B; Xiao W; Yeung C; Hochhaus A
Leukemia; 2022 Jul; 36(7):1703-1719. PubMed ID: 35732831
[TBL] [Abstract][Full Text] [Related]
6.
Ahn JS; Kim HJ
Blood Res; 2022 Apr; 57(S1):32-36. PubMed ID: 35483923
[TBL] [Abstract][Full Text] [Related]
7.
Byun JM; Yoo SJ; Kim HJ; Ahn JS; Koh Y; Jang JH; Yoon SS
Blood Res; 2022 Mar; 57(1):13-19. PubMed ID: 35197370
[TBL] [Abstract][Full Text] [Related]
8. The contributing factors of resistance or sensitivity to epigenetic drugs in the treatment of AML.
Karimi Kelaye S; Najafi F; Kazemi B; Foruzandeh Z; Seif F; Solali S; Alivand MR
Clin Transl Oncol; 2022 Jul; 24(7):1250-1261. PubMed ID: 35076883
[TBL] [Abstract][Full Text] [Related]
9. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
Stomper J; Rotondo JC; Greve G; Lübbert M
Leukemia; 2021 Jul; 35(7):1873-1889. PubMed ID: 33958699
[TBL] [Abstract][Full Text] [Related]
10. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux P; Haase D; Santini V; Sanz GF; Platzbecker U; Mey U;
Ann Oncol; 2021 Feb; 32(2):142-156. PubMed ID: 33221366
[No Abstract] [Full Text] [Related]
12. Improving Cancer Data Interoperability: The Promise of the Minimal Common Oncology Data Elements (mCODE) Initiative.
Osterman TJ; Terry M; Miller RS
JCO Clin Cancer Inform; 2020 Oct; 4():993-1001. PubMed ID: 33136433
[TBL] [Abstract][Full Text] [Related]
13. Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy.
Bond DR; Lee HJ; Enjeti AK
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114584
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic Syndromes.
Cazzola M
N Engl J Med; 2020 Oct; 383(14):1358-1374. PubMed ID: 32997910
[No Abstract] [Full Text] [Related]
15. Role of DNA Methylation in the Resistance to Therapy in Solid Tumors.
Romero-Garcia S; Prado-Garcia H; Carlos-Reyes A
Front Oncol; 2020; 10():1152. PubMed ID: 32850327
[TBL] [Abstract][Full Text] [Related]
16. Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome.
Zhou QB; Liu ZT; Wang HZ; Guo XQ; Xu YG; Hu XM
Drug Des Devel Ther; 2020; 14():1641-1650. PubMed ID: 32431489
[TBL] [Abstract][Full Text] [Related]
17. Expression Profiles of DNA Methylation and Demethylation Machinery Components in Pediatric Myelodysplastic Syndrome: Clinical Implications.
Lamim Lovatel V; de Souza Fernandez C; Ferreira Rodrigues E; de Cassia Tavares R; Sobral da Costa E; Abdelhay E; Coelho Soares Lima S; de Souza Fernandez T
Cancer Manag Res; 2020; 12():543-556. PubMed ID: 32158259
[TBL] [Abstract][Full Text] [Related]
18. Screening and identification of key candidate genes and pathways in myelodysplastic syndrome by bioinformatic analysis.
Le Y
PeerJ; 2019; 7():e8162. PubMed ID: 31803541
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
